Weller, M., Kästner, B., Wick, A., Platten, M., Hüsing, J., & Wick, W. (2015). MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: The DIRECTOR trial. Clinical cancer research, 21(9), . https://doi.org/10.1158/1078-0432.CCR-14-2737
Chicago-Zitierstil (17. Ausg.)Weller, Michael, Bärbel Kästner, Antje Wick, Michael Platten, Johannes Hüsing, und Wolfgang Wick. "MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial." Clinical Cancer Research 21, no. 9 (2015). https://doi.org/10.1158/1078-0432.CCR-14-2737.
MLA-Zitierstil (9. Ausg.)Weller, Michael, et al. "MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial." Clinical Cancer Research, vol. 21, no. 9, 2015, https://doi.org/10.1158/1078-0432.CCR-14-2737.